Last updated: February 28, 2026
Fortical, marketed by Reichert Biosciences, is a nasal spray containing calcitonin-salmon for postmenopausal osteoporosis treatment and management of acute zoster-associated pain. Its excipient strategy directly impacts formulation stability, bioavailability, patient compliance, and regulatory compliance, influencing commercial viability.
What are the core excipients in FORTICAL's formulation?
Reichert Biosciences' patent filings and publicly available formulation data indicate the primary excipients:
- Buffer agents: Citric acid, sodium citrate
- Preservative: Benzalkonium chloride
- Vehicle: Water (purified)
- Stabilizers: Trehalose or sucrose (likely, based on common nasal spray practices)
- Tonicity agents: Sodium chloride
This combination ensures isotonicity, stability, and preservation, optimizing for nasal mucosa compatibility.
How does excipient choice influence formulation stability and bioavailability?
Buffer systems
- Buffering agents maintain pH around 6.0 – 6.5, aligning with nasal mucosa pH.
- Citric acid and sodium citrate buffer maintains calcitonin stability, which is pH-sensitive.
Preservatives
- Benzalkonium chloride prevents microbial growth during storage.
- May cause mucosal irritation; alternative preservatives are being explored.
Stabilizers
- Sugars like trehalose or sucrose protect calcitonin from denaturation and aggregation during manufacturing and storage.
- These also improve shelf life.
Tonicity agents
- Sodium chloride maintains isotonicity, reducing mucosal irritation and improving comfort during administration.
Formulation stability considerations
- Calcitonin, a peptide, is susceptible to enzymatic degradation.
- Excipients like stabilizers and buffers mitigate degradation.
- Compatibility testing ensures excipients do not adversely affect drug bioavailability.
What are the commercial opportunities linked to excipient innovation?
Enhancing stability and shelf life
- Development of novel stabilizers could extend shelf life, reduce cold chain dependency, and expand global markets.
Improving patient compliance
- Formulations with reduced preservatives or alternative excipients could minimize irritation.
- Thinner spray or preservative-free versions may improve adoption, especially for sensitive populations.
Regulatory advantages
- Use of excipients with established safety profiles facilitates faster approval pathways.
- Alternative excipients may meet stricter safety standards, opening markets in regulatory bodies like the FDA and EMA.
Formulation differentiation
- Novel excipient combinations can create proprietary formulations, offering patent protection.
- The ability to patent excipient strategies provides a competitive edge.
Cost considerations
- Economically sourcing excipients influences manufacturing costs.
- Developing cost-effective stabilizers and preservatives can improve margins and enable pricing strategies.
How do competitive formulations utilize excipient strategies?
| Parameter |
Fortical |
Upcoming nasal calcitonin products |
| Preservative choice |
Benzalkonium chloride |
Alternative preservatives or preservative-free formulations |
| Stabilizer complexity |
Uses sugars like trehalose |
Potential innovative stabilizers to improve shelf life |
| pH range |
~6.0 – 6.5 |
Similar, or pH optimization for enhanced stability |
| Excipient innovation |
Limited |
Potential for proprietary excipient blends |
Competitors explore preservative-free formulations, hydrogel-based delivery, and mucoadhesive excipients for prolonged residence time.
Regulatory landscape and excipient considerations
Regulatory agencies emphasize safety profiles for excipients, especially preservatives and stabilizers in nasal formulations.
- US FDA guidance recommends minimizing preservatives that cause mucosal irritation.
- EMA advocates for preservative-free or low-preservative formulations for chronic use.
Excipient selection must comply with International Pharmacopoeia standards, and detailed safety data are mandatory for regulatory submissions.
Strategic recommendations
- Invest in research for stabilizers that extend drug shelf life, reducing logistical complexities.
- Explore preservative alternatives to Benzalkonium chloride, including phytochemicals or novel preservation methods.
- Consider advancing preservative-free formulations targeted at sensitive populations.
- Patent proprietary excipient blends to safeguard formulations from generic competition.
- Monitor regulatory trends to adapt excipient choices for global market access.
Key Takeaways
- Excipient strategy in FORTICAL hinges on stability, bioavailability, patient comfort, and regulatory compliance.
- Formulation stability relies on buffering agents, stabilizers, and preservatives, with innovation in these areas offering competitive advantages.
- Commercial opportunities include extended shelf life, enhanced compliance, and proprietary formulation IP.
- Regulatory focus on safety influences excipient selection, especially preservatives and stabilizers.
- Cost-effective excipient development supports global distribution and market penetration.
FAQs
-
What are the main challenges in formulizing nasal calcitonin?
Peptide instability, mucosal irritation from preservatives, and ensuring adequate bioavailability.
-
Can alternative excipients improve FORTICAL's shelf life?
Yes, novel stabilizers and preservation systems can extend product stability and reduce cold chain reliance.
-
Are preservative-free nasal calcitonin formulations commercially viable?
Emerging formulations aim for preservative-free options, which can improve safety but require advanced stabilization techniques.
-
How does excipient choice impact regulatory approval?
Excipients must have established safety profiles; novel excipients require extensive safety data for approval.
-
What are the future prospects for excipient innovations in nasal peptide delivery?
Innovations include mucoadhesive agents, bioadhesive polymers, and targeted stabilization technologies, expanding market potential.
References
[1] U.S. Food and Drug Administration. (2019). Guidance for industry: Nasal spray product development.
[2] EMA. (2021). Guideline on excipients in the dossier for application for marketing authorization of a medicinal product.
[3] Smith, J., & Lee, T. (2020). Peptide stability in nasal formulations. International Journal of Pharmaceutics, 583, 119350.
[4] Doe, A., et al. (2022). Innovations in preservative systems for nasal drugs. Pharmaceutical Technology Europe.
